Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Researchers Use the ProteOn™ XPR36 system to Study the Mechanisms Underlying Cancer, Alzheimer’s Disease, and Other Conditions

Published: Thursday, September 27, 2012
Last Updated: Thursday, September 27, 2012
Bookmark and Share
Bio-Rad Laboratories, Inc. announces that the ProteOn Webinar Series will continue in fall 2012.

The webinar series showcases the latest cancer and disease research utilizing the ProteOn XPR36 protein interaction array system, an instrument that uses surface plasmon resonance (SPR) to generate rich, label-free kinetic binding data. Previously presented topics include the use of SPR for the identification and characterization of phosphoinositide signaling lipids that have been linked to cancer and in studies aimed at understanding protein misfolding, aggregation, and tissue deposition associated with neurodegenerative conditions such as Alzheimer’s disease.

“The webinars introduced the latest applications of SPR technology for drug discovery workflows and provided valuable updates on the instrument’s software and hardware,” said Dr Ralf J. Hosse, Antibody Engineering Group Leader at Roche Glycart in Switzerland.

Cancer and Alzheimer’s Disease Applications
In a July 2012 webinar, Dr Lily Sommer of the Paterson Institute for Cancer Research in Manchester, U.K., described the identification and characterization of novel phosphoinositide-binding proteins using the ProteOn XPR36 system. Phosphoinositides are signaling lipids whose misregulation has been linked to cancer. The studies were undertaken using Bio-Rad’s ProteOn liposome capturing kit, which uses DNA hybridization to selectively capture liposomes to detect phosphoinositide-protein interactions.

Marco Gobbi of the Mario Negri Institute in Milan, Italy hosted a webinar session titled “Novel Applications of SPR to Study Amyloidogenic Peptides and Proteins.” He discussed novel SPR screening applications for both mutation analysis and investigating the effects anti-amyloidogenic drug candidates. The results of this work were published in the Journal of Biological Chemistry in June 2012.

An increasing number of diseases are now being associated with misfolding, aggregation, and tissue deposition of specific proteins, such as in Alzheimer’s disease. Soluble oligomers of the amyloid-β (Aβ) peptide play a key role in the pathogenesis of Alzheimer’s disease, but their elusive nature makes detection challenging. Gobbi and his team demonstrated that SPR measurements can be particularly useful for the kinetic analysis of the elongation of amyloid fibrils and the detection of soluble oligomeric species, which cannot be achieved by other techniques.  

Best Practices in SPR
The webinar series kicked off with a session that focused on guidelines developed by Professor Gideon Schreiber of the Weizmann Institute of Science in Israel advising researchers on how to best perform label-free interaction analysis. Dr Schreiber is well known in the label-free field and has hosted and chaired many conferences on this topic.

Drug Discovery and Development Applications
Dr Dalia Shezifi, manager of the Bio-Rad Haifa Applications Team in Israel, focused on label-free analysis of small molecules and peptides binding to liposomes. Her work demonstrated how the ProteOn liposome capturing kits have been used to address important issues in drug development, such as the binding of small molecule drugs to liposomes when estimating the intestinal absorptivity of new drugs.

To conclude the series, Gary Ross, a Bio-Rad field application specialist, described how the ProteOn system was used to perform antibody quantification and full protein kinetic analysis in a single 45-minute experiment. This application is an important advance for researchers involved in antibody screening, as it provides rich data in a single experiment on a single platform, saving bench time.

“The presentations were a good way to inspire new ideas and assays that may be performed in the future,” said Johan Nilvebrant, a PhD student at the KTH Royal Institute of Technology in Sweden.

New Season, New Series
Bio-Rad’s next SPR webinar series will take place this fall, kicking off on Sept. 25 with a presentation by Dr Carlotta Chiappa, a research scientist at the DiaSorin Research Center in Geranzano, Italy, on antibody screening for the development of a diagnostic test for Clostridium difficile. In October, Dr Jonathan Popplewell, a Bio-Rad application scientist, will present a webinar focusing on best practices for SPR data processing and downstream analysis. Dr Lisa Scalfone, a postdoctoral researcher at the Stanford University School of Medicine, will talk about how the ProteOn XPR36 system was used in a novel workflow to develop antibodies against the influenza virus. The last speaker in the fall series, Dr Ladislav Bumba, a postdoctoral researcher at the Institute of Microbiology in Prague, Czech Republic, will discuss the analysis of the interactions of bacterial toxins with target cell molecules in bacterial pathogenesis.

Please visit http://bit.ly/PO_Webinar_Registration to register. 

All the webinars from this series can be viewed at http://bit.ly/ProteOn_YouTube.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,400+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Droplet Digital PCR Enables Measurement of Potential Cancer Survival Biomarker
Study paves the way for further research into the role of TIL quantification in immunotherapy and as a cancer survival predictor.
Tuesday, December 10, 2013
Bio-Rad Describes Detailed Neuroblastoma Study Using qPCR Analysis
The study uses examples from neuroblastoma research conducted at Bio-Rad and by researchers at Ghent University, Belgium.
Monday, August 04, 2008
Bio-Rad Launches new Website for Researchers Transfecting Mammalian Cells
Bio-Rad adds ‘Gene Transfer Protocols’ to its Gene Expression Gateway Web-site, dedicated to researchers working with mammalian cells.
Friday, June 27, 2008
A Comparative RNA Quantitation Analysis is Available
Bio-Rad Laboratories, Inc. has announced the availability of a technical paper that compares the performance of Bio-Rad’s Experion™ system to other methods of RNA quantitation.
Friday, March 14, 2008
Scientific News
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
Improving Engineered T-Cell Cancer Treatment
Purdue University researchers may have figured out a way to call off a cancer cell assassin that sometimes goes rogue and assign it a larger tumor-specific "hit list."
Uncovering How Some Breast Cancers Resist Treatment
A targeted therapy for triple-negative breast cancer (TNBC), the most aggressive form of breast cancer, has shown potential promise in a recently published study.
Characterizing Cancerous Genomic Variations
Tested on large tumor genomics database, REVEALER method allows researchers to connect genomics to cell function.
Activating Cancer-Killing Immune Cells
A UCL research team have discovered that cutting off a sleep-switch on immune cells inside a tumour wakes up the cells and enables the immune system to hunt down and destroy cancer.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,400+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!